JenaValve Earns Landmark FDA Approval for Novel Heart Valve System

IRVINE, CA – March 18, 2026 – The U.S. Food and Drug Administration (FDA) today granted premarket approval to JenaValve Technology, Inc. for its Trilogy™ Transcatheter Heart Valve (THV) System, marking a pivotal moment in cardiovascular medicine. The approval establishes the Trilogy system as the first and only transcatheter device in the United States specifically indicated for patients with symptomatic, severe aortic regurgitation (ssAR) who are at high risk for open-heart surgery. This decision opens a new frontier of treatment for tens of thousands of Americans who previously had few viable options.

Aortic regurgitation, a condition where the aortic valve fails to close tightly, causes blood to leak backward into the heart's main pumping chamber. In its severe form, it forces the heart to work harder, leading to debilitating symptoms like fatigue and shortness of breath, and can ultimately result in heart failure and death. While surgical aortic valve replacement (SAVR) has been the traditional gold standard, a significant portion of patients are deemed too frail or sick to withstand the rigors of the procedure.

"This FDA approval is the defining moment for JenaValve and, more importantly, those patients in the United States who have suffered from severe aortic regurgitation with nowhere to turn," said John Kilcoyne, Chief Executive Officer of JenaValve, in a company statement. "For too long, high-risk AR patients were left with limited options. Our Trilogy valve changes that reality."

Engineering a Solution for a Unique Challenge

The breakthrough of the Trilogy system lies in its purpose-built design, which directly addresses the anatomical challenges that have long stymied a transcatheter approach for pure aortic regurgitation. Existing transcatheter aortic valve replacement (TAVR) devices, primarily designed for aortic stenosis (a narrowing of the valve), typically rely on heavy calcium deposits in the valve's annulus for secure anchoring. However, patients with pure AR often lack this calcification, making conventional TAVR devices prone to unstable placement and potential dislodgement.

JenaValve’s engineers circumvented this problem with a proprietary innovation: three radiopaque locators. These small, finger-like components are designed to grasp the patient’s native valve leaflets, providing a secure and stable anchor point independent of calcium. This unique mechanism allows for precise, commissurally aligned placement, which is critical for ensuring a tight seal and minimizing paravalvular regurgitation, or leakage around the valve.

Dr. Martin B. Leon, a leading interventional cardiologist and Global Program Chair of the pivotal ALIGN-AR Trial, highlighted the significance of this design. "The unique design of the Trilogy System — with its locator technology providing secure anchoring even in the absence of calcium — addresses the fundamental challenge that has made AR so difficult to treat," he stated. "This approval establishes a new standard of care for high-risk AR patients and is a landmark achievement for the field of interventional cardiology."

A New Market and a Competitive Disruption

The FDA's decision was based on the successful results of the ALIGN-AR Pivotal Trial, a prospective, multicenter study that assessed the Trilogy system in 700 high-risk patients across 30 U.S. centers. The trial demonstrated remarkable safety and efficacy. The one-year all-cause mortality rate was just 7.7%, vastly superior to the pre-specified performance goal of 25%. Furthermore, technical success was achieved in 94.9% of cases, a significant improvement over the 74-86% success rates seen when conventional TAVR devices are used off-label for this condition.

Patients in the trial also experienced profound clinical benefits, including significant reductions in heart chamber size (left ventricular remodeling), dramatic improvements in functional status, and a higher quality of life that was sustained for up to two years. While the results were overwhelmingly positive, the trial did note a new permanent pacemaker implantation rate of 21.6%, a known complication of TAVR procedures that will remain a key consideration for physicians and patients.

This approval doesn't just represent a clinical victory; it signals a major disruption in the multi-billion-dollar transcatheter heart valve market, long dominated by industry giants Edwards Lifesciences and Medtronic. By securing the first and only dedicated indication for ssAR, JenaValve has carved out an exclusive space in a previously untapped segment. The strategic importance of this technology was underscored just two months ago when the U.S. Federal Trade Commission (FTC) blocked a proposed acquisition of JenaValve by Edwards Lifesciences. The FTC argued the merger would stifle competition for a life-saving device, a move that in retrospect appears to have presaged the significance of today's approval and validated JenaValve's competitive threat.

The Path Forward for Patients and Physicians

JenaValve has announced plans to immediately begin its commercial launch, starting with the experienced clinical sites that participated in the ALIGN-AR trial before expanding to new hospitals nationwide. For cardiac centers, the availability of a dedicated, FDA-approved device for high-risk ssAR patients presents a compelling reason to adopt the technology to offer the most advanced care.

The cardiology community has greeted the news with enthusiasm, with many experts calling it a 'game-changer' for a difficult-to-treat population. The approval provides a validated, less-invasive tool that can deliver transformative outcomes for patients who previously faced a grim prognosis.

As the Trilogy system rolls out, the focus will turn to real-world performance and long-term data collection. While in-vitro testing has demonstrated durability, long-term clinical data will be essential to confirm the valve's performance over many years. Nonetheless, for today, the approval marks a historic step forward, offering a new lease on life for thousands of patients and cementing a new standard of care in the treatment of heart valve disease.